Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

Down 42% in 12 months: Stock Advisor rec Enphase Energy (NASDAQ:ENPH) has been suffering under the Trump administration's ...

CrowdStrike still is feeling the financial impact of the outage, but the company has continued to grow revenue and has kept ...

While real estate, as an asset class, is as popular as it’s ever been, commanding more than US$213 trillion in global market ...

The company is a leader in quantum computing, which holds tremendous potential. If you had invested $10,000 in Rigetti ...

A flawed business model should keep investors away from this stock.

So hardly any stocks are moving lower, and those that are aren't seeing much volume, which can turn into a "sign of excessive bullishness," Thrasher said. At extremes, it turns into a sort-of ...

Ares' closest competitor, Blue Owl Capital (NYSE: OBDC), ended its latest quarter with a NAV of $15.14 per share. That's much closer to Blue Owl's current trading price of $15, and it trades at less ...

The Trade Desk's recent revenue miss has likely given investors an excellent buying opportunity. Target's troubles have ...

The best stocks to invest in often are industry leaders in vast markets. These five stocks are likely to continue making ...

Dow trades flat, S&P 500 and Nasdaq notch records as investors await Tesla, Alphabet earnings and tariff deadline news.

S&P 500 and Nasdaq futures slipped into the red on Tuesday as investors geared up for a whirlwind day of company results and ...